Postoperative radiotherapy (PORT) for early oral cavity cancer (pT1-2,N0-1) : A review
Copyright © 2019. Published by Elsevier B.V..
Early stage (T1-2, N0-1) oral squamous cell carcinoma (OSCC) has a generally favorable prognostic outcome. However, locoregional recurrences can occur in up to 30-35% of patients, and 20% will eventually die of disease. National and international treatment guidelines do not recommend the use of postoperative radiotherapy (PORT) in a setting of early OSCC, and highlight surgery alone as the standard single modality treatment. Notwithstanding, the negative prognostic impact of some adverse pathological features, such as perineural and lymphovascular invasion, poor differentiation, depth of invasion >4 mm, and presence of nodal metastasis, is well known. The advantages of PORT in such scenarios are still debated. The aim of this study was to review the more recent literature to provide evidence on the benefits of PORT in the context of early stage OSCC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:143 |
|---|---|
| Enthalten in: |
Critical reviews in oncology/hematology - 143(2019) vom: 15. Nov., Seite 67-75 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ivaldi, Eliana [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adverse pathological feature |
|---|
| Anmerkungen: |
Date Completed 20.01.2020 Date Revised 20.01.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.critrevonc.2019.08.003 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM301081417 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM301081417 | ||
| 003 | DE-627 | ||
| 005 | 20231225103905.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.critrevonc.2019.08.003 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1003.xml |
| 035 | |a (DE-627)NLM301081417 | ||
| 035 | |a (NLM)31499275 | ||
| 035 | |a (PII)S1040-8428(18)30349-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ivaldi, Eliana |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Postoperative radiotherapy (PORT) for early oral cavity cancer (pT1-2,N0-1) |b A review |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.01.2020 | ||
| 500 | |a Date Revised 20.01.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2019. Published by Elsevier B.V. | ||
| 520 | |a Early stage (T1-2, N0-1) oral squamous cell carcinoma (OSCC) has a generally favorable prognostic outcome. However, locoregional recurrences can occur in up to 30-35% of patients, and 20% will eventually die of disease. National and international treatment guidelines do not recommend the use of postoperative radiotherapy (PORT) in a setting of early OSCC, and highlight surgery alone as the standard single modality treatment. Notwithstanding, the negative prognostic impact of some adverse pathological features, such as perineural and lymphovascular invasion, poor differentiation, depth of invasion >4 mm, and presence of nodal metastasis, is well known. The advantages of PORT in such scenarios are still debated. The aim of this study was to review the more recent literature to provide evidence on the benefits of PORT in the context of early stage OSCC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Adverse pathological feature | |
| 650 | 4 | |a Early stage oral cavity cancer | |
| 650 | 4 | |a Postoperative radiotherapy | |
| 700 | 1 | |a Di Mario, Dalila |e verfasserin |4 aut | |
| 700 | 1 | |a Paderno, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Piazza, Cesare |e verfasserin |4 aut | |
| 700 | 1 | |a Bossi, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Iacovelli, Nicola Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Incandela, Fabiola |e verfasserin |4 aut | |
| 700 | 1 | |a Locati, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Fallai, Carlo |e verfasserin |4 aut | |
| 700 | 1 | |a Orlandi, Ester |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Critical reviews in oncology/hematology |d 1996 |g 143(2019) vom: 15. Nov., Seite 67-75 |w (DE-627)NLM012606006 |x 1879-0461 |7 nnns |
| 773 | 1 | 8 | |g volume:143 |g year:2019 |g day:15 |g month:11 |g pages:67-75 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.critrevonc.2019.08.003 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 143 |j 2019 |b 15 |c 11 |h 67-75 | ||